SAFETY DATA SHEET



1. Identification

Product identifier Iclusig

Other means of identification

Synonyms Ponatinib tablets 10 mg / 15 mg / 30 mg / 45 mg, Iclusig film-coated tablets, Ponatinib

hydrochloride tablets, Ponatinib drug product, AP24534

Recommended use Pharmaceutical product.

This safety data sheet is written to provide health, safety and environmental information for people handling this formulated product in the workplace. It is not intended to provide information relevant to medicinal use of the product. In this instance patients should consult prescribing information/package insert/product label or consult their pharmacist or physician. For health and safety information for individual ingredients used during manufacturing, refer to the appropriate

safety data sheet for each ingredient.

Recommended restrictions All other uses.

Manufacturer/Importer/Supplier/Distributor information

Main Office Takeda Pharmaceutical Company Limited

1-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 103-8668, Japan

SDS Information

US Office 500 Kendall Street, Cambridge, MA 02142, USA

CH Office Thurgauerstrasse 130, 8152 Glattpark-Opfikon (Zurich), Switzerland

E-mail Takeda-SDS@takeda.com

Emergency phone number Call CHEMTREC Day or Night

Within USA and Canada: 1-800-424-9300

Outside USA and Canada: +1 703-741-5970 (collect calls accepted)

From anywhere in the world: +1 703-527-3887

Note) When calling Chemtrec for emergency, first tell the product name on SDS along with the

SDS date.

Note) When transcribing the Chemtrec number to GHS label or others, the above note must be

transcribed together.

2. Hazard(s) identification

Hazards for the product as sold

Physical hazards Not classified.

Hazards for the product as sold

Health hazards Acute toxicity, oral Category 4

Carcinogenicity Category 2
Reproductive toxicity Category 2
Specific target organ toxicity, single exposure Category 1
Specific target organ toxicity, repeated Category 1

exposure

Hazards for the product as sold

Environmental hazards Hazardous to the aquatic environment, acute Category 2

hazard

Hazardous to the aquatic environment,

long-term hazard

Hazards for the product as sold OSHA defined hazards

Not classified.

Label elements



Signal word Danger

Harmful if swallowed. Suspected of causing cancer. Suspected of damaging fertility or the

unborn child. Causes damage to organs. Causes damage to organs through prolonged or repeated exposure. Toxic to aquatic life. Very toxic to aquatic life with long lasting effects.

Precautionary statement

Prevention Obtain special instructions before use. Do not handle until all safety precautions have been read

and understood. Do not breathe dust/fume. Wash thoroughly after handling. Do not eat, drink or

Category 1

smoke when using this product. Avoid release to the environment. Wear protective

gloves/protective clothing/eye protection/face protection.

Response If swallowed: Call a poison center/doctor if you feel unwell. Rinse mouth. IF exposed or

concerned: Call a POISON CENTER/doctor. Collect spillage.

Storage Store locked up.

Disposal Dispose of contents/container in accordance with local/regional/national/international

regulations.

Hazard(s) not otherwise classified (HNOC)

No additional hazards are known to be associated with the expected conditions of use at the time of publication. This document does not address hazards that may arise from uses not

reasonably anticipated by the manufacturer.

Supplemental information Finished Pharmaceutical products in their final packages are not subject to OSHA labeling

requirements.

3. Composition/information on ingredients

Mixtures

Chemical name	CAS number	%
Lactose monohydrate	10039-26-6	*
Microcrystalline cellulose	9004-34-6	*
Ponatinib hydrochloride	1114544-31-8	*
Sodium starch glycolate	9063-38-1	*
Polyethylene oxide	25322-68-3	*
Polyvinyl alcohol	9002-89-5	*
Talc	14807-96-6	*
Titanium dioxide	13463-67-7	*
Colloidal silicon dioxide	7631-86-9	*
Magnesium stearate	557-04-0	*

Composition comments * Proprietary.

The exact percentage (concentration) of composition has been withheld as a trade secret.

4. First-aid measures

Inhalation Move to fresh air. Call a physician if symptoms develop or persist.

Skin contact Wash off with soap and water. Get medical attention if irritation develops and persists.

Eye contact Rinse with water. Get medical attention if irritation develops and persists.

Ingestion Rinse mouth. If vomiting occurs, keep head low so that stomach content doesn't get into the

lungs. Get medical advice/attention if you feel unwell.

Most important symptoms/effects, acute and delayed

Prolonged exposure may cause chronic effects.

Indication of immediate medical attention and special treatment needed

Provide general supportive measures and treat symptomatically. Keep victim warm. Keep victim under observation. Symptoms may be delayed.

General information

IF exposed or concerned: Get medical advice/attention. If you feel unwell, seek medical advice (show the label where possible). Ensure that medical personnel are aware of the material(s) involved, and take precautions to protect themselves. Show this safety data sheet to the doctor in attendance.

5. Fire-fighting measures

Suitable extinguishing media

Water fog. Foam. Dry chemical powder. Carbon dioxide (CO2).

Unsuitable extinguishing media

Do not use water jet as an extinguisher, as this will spread the fire.

Specific hazards arising from the chemical

יווכ

During fire, gases hazardous to health may be formed.

Special protective equipment and precautions for firefighters

Self-contained breathing apparatus and full protective clothing must be worn in case of fire.

Fire fighting equipment/instructions

Use water spray to cool unopened containers. Water runoff can cause environmental damage.

Specific methods

General fire hazards

Use standard firefighting procedures and consider the hazards of other involved materials.

No unusual fire or explosion hazards noted.

6. Accidental release measures

Personal precautions, protective equipment and emergency procedures Keep unnecessary personnel away. Keep people away from and upwind of spill/leak. Wear appropriate protective equipment and clothing during clean-up. Ensure adequate ventilation. Local authorities should be advised if significant spillages cannot be contained. For personal protection, see section 8 of the SDS.

Methods and materials for containment and cleaning up

Prevent product from entering drains.

Large Spills: Stop the flow of material, if this is without risk. Following product recovery, flush area with water.

Small Spills: Clean surface thoroughly to remove residual contamination.

Never return spills to original containers for re-use. Put material in suitable, covered, labeled containers. For waste disposal, see section 13 of the SDS.

Environmental precautions

Avoid release to the environment. Inform appropriate managerial or supervisory personnel of all environmental releases. Prevent further leakage or spillage if safe to do so. Avoid discharge into drains, water courses or onto the ground.

7. Handling and storage

Precautions for safe handling

Obtain special instructions before use. Do not handle until all safety precautions have been read and understood. Do not taste or swallow. Avoid prolonged exposure. When using, do not eat, drink or smoke. Pregnant or breastfeeding women must not handle this product. Should be handled in closed systems, if possible. Provide adequate ventilation. Wear appropriate personal protective equipment. Wash hands thoroughly after handling. Avoid release to the environment. Observe good industrial hygiene practices.

Conditions for safe storage, including any incompatibilities

Store locked up. Store in tightly closed container. Store away from incompatible materials (see Section 10 of the SDS). When quality control required, follow the storage condition specified separately.

8. Exposure controls/personal protection

Occupational exposure limits

US. OSHA Table Z-1 Permissible Exposure Limits (PEL) for Air Contaminants (29 CFR 1910.1000)					
Components	Туре	Value	Form		
Microcrystalline cellulose (CAS 9004-34-6)	PEL	5 mg/m3	Respirable fraction.		
		15 mg/m3	Total dust.		

 Iclusig
 SDS US

 955727
 Version #: 01
 Revision date: - Issue date: 02-December-2025
 3 / 10

Components	Туре	Value	Form
Titanium dioxide (CAS 13463-67-7)	PEL	15 mg/m3	Total dust.
US. OSHA Table Z-3 Permi Components	ssible Exposure Limits (PEL) for Min Type	eral Dusts (29 CFR 1910.1000 Value) Form
Microcrystalline cellulose (CAS 9004-34-6)	TWA	5 mg/m3	Respirable fraction.
		15 mg/m3	Total dust.
		50 mppcf	Total dust.
		15 mppcf	Respirable fraction.
Talc (CAS 14807-96-6)	TWA	0.1 mg/m3	Respirable.
		20 mppcf	
		2.4 mppcf	Respirable.
Titanium dioxide (CAS 13463-67-7)	TWA	5 mg/m3	Respirable fraction.
		15 mg/m3	Total dust.
		50 mppcf	Total dust.
		15 mppcf	Respirable fraction.
US. ACGIH Threshold Lim	it Values (TLV)		
Components	Type	Value	Form
Microcrystalline cellulose (CAS 9004-34-6)	TWA	10 mg/m3	
Talc (CAS 14807-96-6)	TWA	2 mg/m3	Respirable fraction.
Titanium dioxide (CAS 13463-67-7)	TWA	2.5 mg/m3	Respirable finescale particles
		0.2 mg/m3	Respirable nanosca particles
NIOSH. Immediately Dange	erous to Life or Health (IDLH) Values	. as amended	
Components	Туре	Value	
Talc (CAS 14807-96-6)	IDLH	1000 mg/m3	
Titanium dioxide (CAS	IDLH	5000 mg/m3	
13463-67-7)		3333g/3	
US. NIOSH: Pocket Guide	to Chemical Hazards		
Components	Туре	Value	Form
Microcrystalline cellulose (CAS 9004-34-6)	TWA	5 mg/m3	Respirable.
,		10 mg/m3	Total
Talc (CAS 14807-96-6)	TWA	2 mg/m3	Respirable.
US. OARS. Workplace Env	rironmental Exposure Level (WEEL) (Guide	
Components	Туре	Value	
Polyethylene oxide (CAS 25322-68-3)	TWA	10 mg/m3	
ogical limit values	No biological exposure limits noted	for the ingredient(s)	
osure guidelines	Ponatinib hydrochloride (CAS 1114	• • • •	da internal value)
ropriate engineering	Good general ventilation should be	, , , , , , , , , , , , , , , , , , , ,	,
trols	applicable, use process enclosures maintain airborne levels below reco	local exhaust ventilation, or oth	er engineering controls t

 Iclusig
 SDS US

 955727
 Version #: 01
 Revision date: - Issue date: 02-December-2025
 4 / 10

established, maintain airborne levels to an acceptable level.

Individual protection measures, such as personal protective equipment

Eye/face protection If contact is likely, safety glasses with side shields are recommended.

Skin protection

Hand protection Wear appropriate chemical resistant gloves.

Impervious oil/water/chemical-resistant gloves (nitrile, etc.).

Gloves meeting EN374, ASTM F1001 or international equivalent standard are recommended.

Skin protection

Other Use of an impervious apron is recommended.

Respiratory protection In case of insufficient ventilation, wear suitable respiratory equipment. In the United States of

> America, if respirators are used, a program should be instituted to assure compliance with OSHA 29 CFR 1910.134. Seek advice from supervisor on the company's respiratory protection

standards.

Thermal hazards Wear appropriate thermal protective clothing, when necessary.

Observe any medical surveillance requirements. Keep away from food and drink. Always observe General hygiene considerations

> good personal hygiene measures, such as washing after handling the material and before eating, drinking, and/or smoking. Routinely wash work clothing and protective equipment to

remove contaminants.

9. Physical and chemical properties

Physical state

Form Film-coated tablets. Color No data available. Odor No data available.

Odor threshold Property has not been measured. Melting point/freezing point Property has not been measured. Boiling point or initial boiling

point and boiling range

Property has not been measured.

Flammability Will burn if involved in a fire.

Upper/lower flammability or explosive limits

Explosive limit - lower (%) Not applicable, material is a solid. Explosive limit - upper (%) Not applicable, material is a solid.

Flash point Property has not been measured. **Auto-ignition temperature** Not applicable, material is a solid. **Decomposition temperature** Property has not been measured. Ha Property has not been measured. Kinematic viscosity Not applicable, material is a solid.

Solubility

Solubility (water) Property has not been measured. **Partition coefficient** Not applicable, product is a mixture.

(n-octanol/water) Vapor pressure

Not applicable, material is a solid.

Density and/or relative density

Density Property has not been measured. Relative density Property has not been measured. Vapor density Not applicable, material is a solid.

Particle characteristics

Particle size Property has not been measured.

Other information

Evaporation rate Not applicable, material is a solid.

Explosive properties Not explosive.

SDS US Iclusig 5 / 10

Oxidizing properties Not oxidizing.

Viscosity Not applicable, material is a solid.

10. Stability and reactivity

Reactivity The product is stable and non-reactive under normal conditions of use, storage and transport.

Chemical stability Material is stable under normal conditions.

Possibility of hazardous

reactions

No dangerous reaction known under conditions of normal use.

Conditions to avoid Contact with incompatible materials. Incompatible materials Strong acids, alkalis and oxidizing agents.

Hazardous decomposition

products

No hazardous decomposition products are known.

11. Toxicological information

Information on likely routes of exposure

Inhalation No adverse effects due to inhalation are expected. Skin contact Prolonged skin contact may cause temporary irritation. Eye contact Direct contact with eyes may cause temporary irritation.

Ingestion Harmful if swallowed.

Symptoms related to the physical, chemical and toxicological characteristics Prolonged exposure may cause chronic effects.

Information on toxicological effects

Harmful if swallowed. **Acute toxicity**

Ponatinib hydrochloride (CAS 1114544-31-8) Result: The oral LD50 in rats is estimated to be 55 mg/kg.

Test Results Components **Species**

Polyethylene oxide (CAS 25322-68-3)

Acute

Dermal

LD50 Rabbit > 20000 mg/kg

Inhalation

LC50 Rat > 1008 mg/m³, 4 Hours

Oral

LD50 Mouse 6400 mg/kg Rat 17300 mg/kg

Ponatinib hydrochloride (CAS 1114544-31-8)

Acute Oral

LD50 Rat 55 mg/kg Estimate

Skin corrosion/irritation No data available. Serious eye damage/eye No data available.

irritation

Respiratory or skin sensitization

Respiratory sensitization No data available. Skin sensitization No data available. Germ cell mutagenicity Not classified.

Mutagenicity

Ponatinib hydrochloride (CAS 1114544-31-8) Bacterial Reverse Mutation Test (Ames Assay)

Result: Negative.

SDS US Iclusig 6 / 10

Mutagenicity

In vitro Chromosome Aberration Ponatinib hydrochloride (CAS 1114544-31-8)

> Result: Negative. Species: Human Organ: Lymphocytes In vivo Micronucleus Result: Negative. Species: Mouse

Carcinogenicity

Suspected of causing cancer.

Ponatinib hydrochloride (CAS 1114544-31-8)

Result: 1. In a two-year oral carcinogenicity study in rats, female rats developed squamous cell carcinoma of the clitoral gland at 0.8 mg/kg/day.

Result: 2. An increased incidence of sex cord stromal hyperplasia and mixed sex cord stromal benian ovarian tumors was observed at 0.4 and 0.8 mg/kg/day.

Result: 3. Ponatinib was not found to be carcinogenic in male

IARC Monographs. Overall Evaluation of Carcinogenicity

Talc (CAS 14807-96-6)

Titanium dioxide (CAS 13463-67-7)

2A Probably carcinogenic to humans. 2B Possibly carcinogenic to humans.

NTP Report on Carcinogens

Not listed.

OSHA Specifically Regulated Substances (29 CFR 1910.1001-1053)

Not listed.

Reproductive toxicity

Suspected of damaging fertility or the unborn child.

Reproductivity

Ponatinib hydrochloride (CAS 1114544-31-8)

Result: 1. Oral fertility and early embryonic development study in rats: The NOAEL for reproductive performance and fertility was 1.50 mg/kg/day in males and 0.75 mg/kg/day in females.

Result: 2. Ponatinib had no effect on male fertility parameters, but decreased female fertility parameters as indicated by increased pre- and post-implantation embryo-fetal lethality in the rats dosed with 1.50 mg/kg/day ponatinib.

Result: 3. Oral embryo-fetal developmental study in rats: The NOAEL for embryo-fetal development impairment was 0.3 mg/kg/day.

Result: 4. Embryo-fetal toxicity manifested as

post-implantation loss and reduced fetal body weights at 3 mg/kg/day and fetal alterations (soft tissue and skeletal malformations and variations) at 1 and 3 mg/kg/day.

Specific target organ toxicity -Causes damage to organs. single exposure

Ponatinib hydrochloride (CAS 1114544-31-8)

Result: 1. Toxicity studies were conducted in mice, rats, and monkeys. Ponatinib was tolerated up to 450 mg/kg in mice. In rats, lymphoid depletion was noted consistent with bacterial sepsis, skin findings, and hematologic findings.

Result: 2. Monkeys presented with follicular atrophy of the thyroid gland and hyperkeratosis. LOAEL estimated <100

mg/kg.

Specific target organ toxicity -Causes damage to organs through prolonged or repeated exposure. repeated exposure

Ponatinib hydrochloride (CAS 1114544-31-8)

Result: 1. Toxicology studies in rats and monkeys indicated the following key target organs of ponatinib toxicity: pancreas, lymphoid organs, bone, skin, thyroid gland, testes, and ovaries.

Result: 2. Six months oral study in rat, NOAEL = 0.25

Iclusig 955727 Version #: 01 Revision date: -Issue date: 02-December-2025 Specific target organ toxicity - repeated exposure

Ponatinib hydrochloride (CAS 1114544-31-8)

Result: 3. Six months oral study in monkey, NOAEL <0.25

mg/kg/day.

Aspiration hazard Not relevant, due to the form of the product.

Chronic effectsCauses damage to organs through prolonged or repeated exposure.

12. Ecological information

Ecotoxicity Toxic to aquatic life. Very toxic to aquatic life with long lasting effects.

Components Species Test Results

Ponatinib hydrochloride (CAS 1114544-31-8)

Aquatic

Acute

Algae EC50 Pseudokirchneriella subcapitata 0.677 mg/l, 72 hours

NOEC Pseudokirchneriella subcapitata 0.14 mg/l, 72 hours

Chronic

Crustacea NOEC Daphnia magna 0.04 mg/l, 21 days
Fish NOEC Zebrafish (Danio rerio) 0.0012 mg/l, 30 days

Persistence and degradability
No data is available on the degradability of this product.

Ponatinib hydrochloride: Not readily biodegradable.

Bioaccumulative potential

Partition coefficient n-octanol / water (log Kow)

Ponatinib hydrochloride (CAS 1114544-31-8) 4.5 log Pow @ pH 7 (OECD TG 123)

Mobility in soilNo data available.Other adverse effectsNo data available.

13. Disposal considerations

Disposal instructionsCollect and reclaim or dispose in sealed containers at licensed waste disposal site. Do not

allow this material to drain into sewers/water supplies. Do not contaminate ponds, waterways or ditches with chemical or used container. Dispose of contents/container in accordance with

local/regional/national/international regulations.

Local disposal regulations Dispose in accordance with all applicable regulations.

Hazardous waste code

The waste code should be assigned in discussion between the user, the producer and the

waste disposal company.

Waste from residues / unused

products

Dispose of in accordance with local regulations. Empty containers or liners may retain some product residues. This material and its container must be disposed of in a safe manner.

Contaminated packaging Since emptied containers may retain product residue, follow label warnings even after container

is emptied. Empty containers should be taken to an approved waste handling site for recycling or

disposal.

14. Transport information

DOT

UN number UN3077

UN proper shipping name

Environmentally hazardous substances, solid, n.o.s. (Ponatinib hydrochloride)

Transport hazard class(es)

Class 9
Subsidiary hazard Label(s) 9
Packing group III

Environmental hazards

Marine pollutant Ye

Special precautions for user Read safety instructions, SDS and emergency procedures before handling.

Special provisions 8, 146, 335, A112, B54, IB8, IP3, N20, T1, TP33

Packaging exceptions 155
Packaging non bulk 213

Packaging bulk 240

IATA

UN number UN3077

UN proper shipping name Environmentally hazardous substance, solid, n.o.s. (Ponatinib hydrochloride)

Transport hazard class(es)

Class 9 Subsidiary hazard 9 Label(s) Packing group Ш **Environmental hazards** Yes **FRG Code** 91

Special precautions for user Read safety instructions, SDS and emergency procedures before handling.

IMDG

UN number UN3077

UN proper shipping name ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ponatinib hydrochloride)

Transport hazard class(es)

Class 9 **Subsidiary hazard** Label(s) 9 Ш Packing group **Environmental hazards**

Marine pollutant Yes **EmS** F-A. S-F

Special precautions for user Read safety instructions, SDS and emergency procedures before handling.

Transport in bulk according to

Not applicable.

IMO instruments

15. Regulatory information

US federal regulations This product is a "Hazardous Chemical" as defined by the OSHA Hazard Communication

Standard, 29 CFR 1910,1200.

All components are listed on or exempt from the U.S. EPA TSCA Inventory List.

This product may only be used for TSCA Exempt purposes such as R&D or Food, Drug or

All components are either listed on the TSCA 8(b) inventory and

Cosmetic use.

designated "active" or exempt from listing.

TSCA Section 12(b) Export Notification (40 CFR 707, Subpt. D)

Not regulated.

CERCLA Hazardous Substance List (40 CFR 302.4)

Not listed.

SARA 304 Emergency release notification

Toxic Substances Control Act (TSCA)

Not regulated.

OSHA Specifically Regulated Substances (29 CFR 1910.1001-1053)

Not listed.

Superfund Amendments and Reauthorization Act of 1986 (SARA)

SARA 302 Extremely hazardous substance

Not listed.

SARA 311/312 Hazardous

No (Exempt)

chemical

SARA 313 (TRI reporting)

Not regulated.

Other federal regulations

Clean Air Act (CAA) Section 112 Hazardous Air Pollutants (HAPs) List

Not regulated.

SDS US Iclusig

Clean Air Act (CAA) Section 112(r) Accidental Release Prevention (40 CFR 68.130)

Not regulated.

Safe Drinking Water Act

Not regulated.

(SDWA)

US state regulations

US. California. Candidate Chemicals List. Safer Consumer Products Regulations (Cal. Code Regs, tit. 22, 69502.3, subd. (a))

Talc (CAS 14807-96-6)

Titanium dioxide (CAS 13463-67-7)

US. Massachusetts RTK - Substance List

Microcrystalline cellulose (CAS 9004-34-6)

Talc (CAS 14807-96-6)

Titanium dioxide (CAS 13463-67-7)

US. New Jersey Worker and Community Right-to-Know Act

Microcrystalline cellulose (CAS 9004-34-6)

Talc (CAS 14807-96-6)

Titanium dioxide (CAS 13463-67-7)

US. Pennsylvania Worker and Community Right-to-Know Law

Microcrystalline cellulose (CAS 9004-34-6)

Talc (CAS 14807-96-6)

Titanium dioxide (CAS 13463-67-7)

US. Rhode Island RTK

Microcrystalline cellulose (CAS 9004-34-6)

Talc (CAS 14807-96-6)

Titanium dioxide (CAS 13463-67-7)

California Proposition 65



WARNING: This product can expose you to Titanium dioxide, which is known to the State of California to

cause cancer. For more information go to www.P65Warnings.ca.gov.

California Proposition 65 - CRT: Listed date/Carcinogenic substance

Titanium dioxide (CAS 13463-67-7) Listed: September 2, 2011

16. Other information, including date of preparation or last revision

Issue date 02-December-2025

Revision date - Version # 01

References IARC Monographs. Overall Evaluation of Carcinogenicity

In-house data.

Disclaimer Takeda Pharmaceutical Company Limited cannot anticipate all conditions under which this

information and its product, or the products of other manufacturers in combination with its product, may be used. It is the user's responsibility to ensure safe conditions for handling, storage and disposal of the product, and to assume liability for loss, injury, damage or expense due to improper use. The information in the sheet was written based on the best knowledge and

experience currently available.